{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:37:12Z","timestamp":1790390232352,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transactions of the Royal Society of Tropical Medicine and Hygiene"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.trstmh.2006.03.009","type":"journal-article","created":{"date-parts":[[2006,8,15]],"date-time":"2006-08-15T12:06:29Z","timestamp":1155643589000},"page":"S4-S8","source":"Crossref","is-referenced-by-count":136,"special_numbering":"S1","title":["Miltefosine \u2013 discovery of the antileishmanial activity of phospholipid derivatives"],"prefix":"10.1093","volume":"100","author":[{"given":"Simon L.","family":"Croft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.trstmh.2006.03.009_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0166-6851(87)90146-0","article-title":"Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes","volume":"23","author":"Achterberg","year":"1987","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.trstmh.2006.03.009_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0166-6851(87)90080-6","article-title":"Metabolism of ether lysophospholipids in Leishmania donovani promastigotes","volume":"26","author":"Achterberg","year":"1987","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.trstmh.2006.03.009_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4269\/ajtmh.1985.34.270","article-title":"Enhancement of Glucantime therapy of murine Leishmania donovani infection by a synthetic immunopotentiating compound (CP-46,65-1)","volume":"34","author":"Adinolfi","year":"1985","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.trstmh.2006.03.009_bib4","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1021\/jm020972c","article-title":"Antileishmanial ring-substituted ether phospholipids","volume":"46","author":"Avlonitis","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.trstmh.2006.03.009_bib5","first-page":"1037","article-title":"Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine","volume":"289","author":"Benveniste","year":"1979","journal-title":"C. R. Seances Acad. Sci. D"},{"key":"10.1016\/j.trstmh.2006.03.009_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/00034983.1996.11813083","article-title":"Antileishmanial activity of rac-1-dodecyl-2-octanamido-2-deoxy-glycerophosphocholine, a new dialkylglycerophosphocholine, in vitro","volume":"90","author":"Bourass","year":"1996","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/j.trstmh.2006.03.009_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0163-7258(95)00001-W","article-title":"Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells","volume":"66","author":"Brachwitz","year":"1995","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.trstmh.2006.03.009_bib8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0165-6147(86)90401-3","article-title":"PAF-acether specific binding sites: 2. Design of specific antagonists","volume":"7","author":"Braquet","year":"1986","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.trstmh.2006.03.009_bib9","first-page":"59","article-title":"Overview on the clinical development of miltefosine solution (Miltex\u00ae) for the treatment of cutaneous breast cancer","volume":"30","author":"Burk","year":"1994","journal-title":"Drugs Today"},{"key":"10.1016\/j.trstmh.2006.03.009_bib10","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/0006-2952(87)90543-0","article-title":"The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani","volume":"36","author":"Croft","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.trstmh.2006.03.009_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0035-9203(93)90499-G","article-title":"Antileishmanial activity of the ether phospholipid ilmofosine","volume":"87","author":"Croft","year":"1993","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.trstmh.2006.03.009_bib12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/jac\/38.6.1041","article-title":"The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei","volume":"38","author":"Croft","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.trstmh.2006.03.009_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/1381612023396258","article-title":"Chemotherapy of leishmaniasis","volume":"8","author":"Croft","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.trstmh.2006.03.009_bib14","doi-asserted-by":"crossref","first-page":"9355","DOI":"10.1016\/S0021-9258(19)83523-8","article-title":"Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators)","volume":"254","author":"Demopoulos","year":"1979","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trstmh.2006.03.009_bib15","first-page":"201","article-title":"PAF-receptor. 1. \u2018Cache-oreilles\u2019 effect of selected high-potency platelet-activating factor (PAF) antagonists","volume":"1","author":"Dive","year":"1989","journal-title":"J. Lipid. Mediat."},{"key":"10.1016\/j.trstmh.2006.03.009_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0305-7372(90)90053-I","article-title":"Hexadecylphosphocholine: a new and selective antitumor drug","volume":"17","author":"Eibl","year":"1990","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.trstmh.2006.03.009_bib17","first-page":"5","article-title":"Miltefosine, the story of a successful partnership: disease endemic country \u2013 TDR \u2013 pharmaceutical industry (Zentaris)","volume":"68","author":"Engel","year":"2002","journal-title":"TDR News"},{"key":"10.1016\/j.trstmh.2006.03.009_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0001-706X(01)00197-8","article-title":"Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B","volume":"81","author":"Escobar","year":"2002","journal-title":"Acta Trop."},{"key":"10.1016\/j.trstmh.2006.03.009_bib19","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1128\/AAC.45.6.1872-1875.2001","article-title":"Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice","volume":"45","author":"Escobar","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.trstmh.2006.03.009_bib20","first-page":"2","article-title":"Oral miltefosine may revolutionize treatment of visceral leishmaniasis","volume":"68","author":"Ganguly","year":"2002","journal-title":"TDR News"},{"key":"10.1016\/j.trstmh.2006.03.009_bib21","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/1078-0432.CCR-0837-02","article-title":"Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors","volume":"15","author":"Giantonio","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trstmh.2006.03.009_bib22","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0165-6147(86)90388-3","article-title":"PAF-acether specific binding sites: 1. quantitative SAR study of PAF-acether isosters","volume":"7","author":"Godfroid","year":"1986","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.trstmh.2006.03.009_bib23","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/BF02536523","article-title":"PAF receptor structure: A hypothesis","volume":"26","author":"Godfroid","year":"1991","journal-title":"Lipids"},{"key":"10.1016\/j.trstmh.2006.03.009_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0166-6851(82)90042-1","article-title":"Metabolism of 1-O-[1\u2032-14C]octadecyl-sn-glycerol in Leishmania donovani promastigotes. Ether lipid synthesis and degradation of the ether bond","volume":"5","author":"Herrmann","year":"1982","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.trstmh.2006.03.009_bib25","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/0277-5379(88)90336-7","article-title":"Characterization of the antitumor activity of hexadecylphosphocholine (D 18506)","volume":"24","author":"Hilgard","year":"1988","journal-title":"Eur. J. Clin. Oncol."},{"key":"10.1016\/j.trstmh.2006.03.009_bib26","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0959-8049(97)89020-X","article-title":"D-21266, a new heterocyclic alkylphospholipid with antitumor activity","volume":"33","author":"Hilgard","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trstmh.2006.03.009_bib27","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1128\/AAC.36.8.1630","article-title":"Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice","volume":"36","author":"Kuhlencord","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.trstmh.2006.03.009_bib28","first-page":"230","article-title":"PAF-receptor. III. Conformational and electronic properties of PAF-like agonists and antagonists","volume":"666","author":"Lamotte-Brasseur","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.trstmh.2006.03.009_bib29","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.42.3.654","article-title":"Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB\/c mice","volume":"42","author":"Le Fichoux","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.trstmh.2006.03.009_bib30","first-page":"411","article-title":"Lysolecithin analogs: a new class of immunopotentiators","volume":"7","author":"Munder","year":"1977","journal-title":"Immunopathology"},{"key":"10.1016\/j.trstmh.2006.03.009_bib31","series-title":"Augmenting agents in Cancer Therapy","first-page":"441","article-title":"Alkyl-lysophospholipids in cancer therapy","author":"Munder","year":"1981"},{"key":"10.1016\/j.trstmh.2006.03.009_bib32","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1128\/AAC.44.11.3235-3236.2000","article-title":"Suppression of posttreatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine","volume":"44","author":"Murray","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.trstmh.2006.03.009_bib33","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1086\/315268","article-title":"Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms","volume":"181","author":"Murray","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.trstmh.2006.03.009_bib34","doi-asserted-by":"crossref","first-page":"49965","DOI":"10.1074\/jbc.M308352200","article-title":"Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance","volume":"278","author":"Perez-Victoria","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trstmh.2006.03.009_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0035-9203(99)90192-X","article-title":"Topical treatment with hexadecylphosphocholine (Miltex\u00ae) efficiently reduces parasite burden in experimental cutaneous leishmaniasis","volume":"93","author":"Schmidt-Ott","year":"1999","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.trstmh.2006.03.009_bib36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0924-8579(03)00125-0","article-title":"Characterization of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine)","volume":"22","author":"Seifert","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.trstmh.2006.03.009_bib37","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","article-title":"Trial of miltefosine for visceral leishmaniasis","volume":"352","author":"Sundar","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.trstmh.2006.03.009_bib38","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1248\/cpb.30.3260","article-title":"Syntheses and antimicrobial activities of alkyl lysophospholipids","volume":"30","author":"Tsushima","year":"1982","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.trstmh.2006.03.009_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/02841868909111249","article-title":"Hexadecylphosphocholine, a new etherlipid analogue: studies on the antineoplastic activity in vitro and in vivo","volume":"28","author":"Unger","year":"1989","journal-title":"Acta Oncol."},{"issue":"Suppl. F","key":"10.1016\/j.trstmh.2006.03.009_bib40","first-page":"133","article-title":"In vivo antileishmanial activity of hexadecylphosphocholine and other alkylphosphocholines","volume":"34","author":"Unger","year":"1998","journal-title":"Drugs Today"},{"issue":"Suppl. 1","key":"10.1016\/j.trstmh.2006.03.009_bib41","article-title":"Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites","volume":"100","author":"Urbina","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.trstmh.2006.03.009_bib42","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/BF02535532","article-title":"Ether lipids in oncology \u2013 welcoming address","volume":"22","author":"Westphal","year":"1987","journal-title":"Lipids"},{"key":"10.1016\/j.trstmh.2006.03.009_bib43","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4269\/ajtmh.2005.73.272","article-title":"The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine","volume":"73","author":"Yardley","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."}],"container-title":["Transactions of the Royal Society of Tropical Medicine and Hygiene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/trstmh\/article-pdf\/100\/Supplement_1\/S4\/5329861\/100-Supplement_1-S4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T12:02:52Z","timestamp":1627732972000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/trstmh\/article-lookup\/doi\/10.1016\/j.trstmh.2006.03.009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":43,"alternative-id":["S0035920306001970"],"URL":"https:\/\/doi.org\/10.1016\/j.trstmh.2006.03.009","relation":{},"ISSN":["0035-9203"],"issn-type":[{"value":"0035-9203","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}